Stockreport

GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster

GeoVax Labs, Inc.  (GOVX) 
NASDAQ:AMEX Investor Relations: geovax.com/contact-geovax.html
PDF Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs [Read more]